Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 219-535-8 | CAS number: 2457-01-4
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
Additional information
Eight female rats received a single dose of either 100 or 1000 mg/kg radiolabeled 2-ethylhexanoic acid by gavage. Four female rats received doses of 100 mg/kg radiolabeled 2-ethylhexanoic acid by gavage for 15 days. Eight female rats received a single dermal application of either 100 or 1000 mg/kg radiolabeled 2-ethylhexanoic acid. Eight female rats received a single intravenous application of 1 mg/kg radiolabeled 2-ethylhexanoic acid.
After oral administration of 2-ethylhexanoic acid, peak blood levels are achieved after 15-30 minutes, and declined triphasically with half-lives of ca. 0.3, 7 and 98 h. Approximately 72-75% of the oral dose was excreted in the urine within 24 hours. Little radioactivity (<10%) was excreted after 24 hours. The dose influenced the rate of excretion such that 50% of the radioactivity was excreted in the first 8 hours after the 100 mg/kg dose versus 20% after the 1000 mg/kg dose. Faecal excretion accounted for 7-12% in both cases. Repeated dosing with unlabelled 2-ethylhexanoic acid altered excretion of radioactivity to approximately 55% in urine and 15% in faeces within the first 24 hours.
Dermal application of 2-ethylhexanoic acid results in slower absorption with peak blood levels occurring 5.7 hours after application and a half-life of approximately 3 hours. Elimination is bi-phasic with half-lifes of ca. 4 and 251 hours. After dermal application, approximately 30% of the dose was excreted in the urine during the first 24 hours followed by an additional 8 or 17% from 24-96 hours for the 100 and 1000 mg/kg doses, respectively. After dermal application, approximately 30% of the dose was excreted in the urine during the first 24 hours followed by an additional 8 or 17% from 24-96 hours for the 100 and 1000 mg/kg doses, respectively. Faecal excretion was 7% regardless of the dose level. Dermal absorption was estimated to be 63-70% relative to intravenous administration.
Blood levels after intravenous injection appear to decay in a triphasic manner with half-lives of 0.2, 6.6, and 117 hours. Slightly less radioactivity was excreted as either urine (64%) or faeces (2%) after intravenous injection, compared to oral administration.
2-Ethylhexanoic acid is excreted via the urine as a glucuronide conjugate of 2-ethylhexanoic acid, as a glucuronide conjugate of hydroxylated and diacid derivatives of 2-ethylhexanoic acid (possibly 2-ethyl-6-hydroxyhexanoic acid and 2-ethyl-1,6-hexanedioic acid), and for a very minor part as unmetabolized 2-ethylhexanoic acid (English et al., 1987).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
